Fetal cell carcinogenesis of the thyroid: A modified theory based on recent evidence

Endocrine Journal

Volumn 61, Issue 4, 2014, Pages 311-320

  Takano, Toru ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immature cancer; Progenitor; Reverse approach; Stem cell crisis; Thyroid cancer

Indexed keywords

B RAF KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED; PROTEIN RET; TRANSCRIPTION FACTOR PAX8;

ARTICLE; BRAF GENE; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHERNOBYL ACCIDENT; DIFFERENTIATED THYROID CANCER; FETUS CELL; GENE MUTATION; GENE REARRANGEMENT; HUMAN; NONHUMAN; PAX8 GENE; PPARG1 GENE; PROTHYROCYTE; PTC GENE; RADIATION CARCINOGENESIS; RET GENE; STEM CELL; THYROBLAST; THYROID CANCER; THYROID CANCER INITIATING CELL; THYROID CARCINOMA; THYROID CELL; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID STEM CELL; ADULT STEM CELL; ANIMAL; BIOLOGICAL MODEL; EMBRYOLOGY; FETAL STEM CELL; ORGANOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; THYROID GLAND; THYROID TUMOR;

ADULT STEM CELLS; ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; FETAL STEM CELLS; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; ORGANOGENESIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84899682801     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0517     Document Type: Article

References (57)

1. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306.
2. Takano T, Amino N (2002) Cancer-specific mRNAs in thyroid carcinomas: detection, use, and their implication in thyroid carcinogenesis. Endocr J 49: 97-107.
3. Takano T (2004) Fetal cell carcinogenesis of the thyroid: a hypothesis for better understanding of gene expression profile and genomic alternation in thyroid carcinoma. Endocr J 51: 509-515.
4. Takano T, Amino N (2005) Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. Thyroid 15: 432-438.
5. Takano T (2007) Fetal cell carcinogenesis of the thyroid: theory and practice. Semin Cancer Biol 17: 233-240.
6. Klonisch T, Hoang-Vu C, Hombach-Klonisch S (2009) Thyroid stem cells and cancer. Thyroid 19: 1303-1315.
7. Davies TF, Latif R, Minsky NC, Ma R (2011) Clinical review: The emerging cell biology of thyroid stem cells. J Clin Endocrinol Metab 96: 2692-2702.
8. Lin RY (2011) Thyroid cancer stem cells. Nat Rev Endocrinol 7: 609-616.
9. Wallin G, Backdahl M, Christensson B, Grimelius L, Auer G (1992) Nuclear protein content and Ki-67 immunoreactivity in nonneoplastic and neoplastic thyroid cells. Anal Quant Cytol Histol 14: 296-303.
10. Nikiforov Y, Gnepp DR, Fagin JA (1996) Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab 81: 9-14.
11. Holm LE, Dahlqvist I, Israelsson A, Lundell G (1980) Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N Engl J Med 303: 188-191.
12. Saad AG, Kumar S, Ron E, Lubin JH, Stanek J, et al. (2006) Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab 91: 2672-2677.
13. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, et al. (1995) RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11: 1207-1210.
14. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, et al. (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289: 1357-1360.
15. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, et al. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397.
16. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, et al. (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22: 6455-6457.
17. Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A (2007) BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96: 1549-1553.
18. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, et al. (2007) Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27: 3645-3649.
19. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, et al. (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89-97.
20. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, et al. (2010) An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34: 28-35.
21. Trueba SS, Auge J, Mattei G, Etchevers H, Martinovic J, et al. (2005) PAX8, TITF1, and FOXE1 gene expression patterns during human development: new insights into human thyroid development and thyroid dysgenesis-associated malformations. J Clin Endocrinol Metab 90: 455-462.
22. Sugino K, Mimura T, Ozaki O, Kure Y, Iwasaki H, et al. (1995) Early recurrence of hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy. World J Surg 19: 648-652.
23. Bocian-Sobkowska J, Malendowicz LK, Wozniak W (1992) Morphometric studies on the development of human thyroid gland in early fetal life. Histol Histopathol 7: 415-420.
24. Matsuura H, Hakomori S (1985) The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci U S A 82: 6517-6521.
25. Takano T, Matsuzuka F, Sumizaki H, Kuma K, Amino N (1997) Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res 57: 3792-3797.
26. Takano T, Matsuzuka F, Miyauchi A, Yokozawa T, Liu G, et al. (1998) Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study. Br J Cancer 78: 221-224.
27. Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, et al. (2007) Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma. Jpn J Clin Oncol 37: 647-651.
28. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, et al. (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158: 375-384.
29. Kjellev S (2009) The trefoil factor family-small peptides with multiple functionalities. Cell Mol Life Sci 66: 1350-1369.
30. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N (2004) High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer 90: 1600-1605.
31. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N (2005) Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma. Cancer Lett 219: 91-96.
32. Wattel S, Mircescu H, Venet D, Burniat A, Franc B, et al. (2005) Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene 24: 6902-6916.
33. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, et al. (1996) Targeted expression of the ret/ PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137: 375-378.
34. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M (2011) Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 71: 3863-3871.
35. Shimamura M, Nakahara M, Orim F, Kurashige T, Mitsutake N, Nakashima M, Kondo S, Yamada M, Taguchi R, Kimura S, Nagayama Y (2013) Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma. Endocrinology 154: 4423-4430.
36. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, et al. (2010) Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 70: 8874-8885.
37. Rojeski MT, Gharib H (1985) Nodular thyroid disease. Evaluation and management. N Engl J Med 313: 428-436.
38. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM (1998) Na+/I-symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83: 4102-4106.
39. Harach HR, Franssila KO, Wasenius VM (1985) Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56: 531-538.
40. Ito Y, Miyauchi A, Kihara M, Takamura Y, Kobayashi K, et al. (2012) Relationship between prognosis of papillary thyroid carcinoma patient and age: a retrospective single-institution study. Endocr J 59: 399-405.
41. Kowalski LP, Goncalves Filho J, Pinto CA, Carvalho AL, de Camargo B (2003) Long-term survival rates in young patients with thyroid carcinoma. Arch Otolaryngol Head Neck Surg 129: 746-749.
42. Neff RL, Farrar WB, Kloos RT, Burman KD (2008) Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37: 525-538.
43. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
44. Shiras A, Chettiar ST, Shepal V, Rajendran G, Prasad GR, et al. (2007) Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 25: 1478-1489.
45. Torsvik A, Rosland GV, Bjerkvig R (2012) Spontaneous transformation of stem cells in vitro and the issue of cross-contamination. Int J Biol Sci 8: 1051-1052; discussion 1053-1054.
46. Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, et al. (2013) Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. FASEB J 27: 2788-2798.
47. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
48. Neureiter D, Herold C, Ocker M (2006) Gastrointestinal cancer-only a deregulation of stem cell differentiation? Int J Mol Med 17: 483-489.
49. Axelson H, Johansson ME (2013) Renal stem cells and their implications for kidney cancer. Semin Cancer Biol 23: 56-61.
50. Yoon SK (2012) The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma. Gut Liver 6: 29-40.
51. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, et al. (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26: 504-524.
52. Thomas T, Nowka K, Lan L, Derwahl M (2006) Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid glands. Thyroid 16: 537-544.
53. Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, et al. (1984) Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyroninepredominant Graves' disease. Ann Intern Med 100: 372-375.
54. Matsumoto C, Ito M, Yamada H, Yamakawa N, Yoshida H, et al. (2013) Genes that characterize T3-predominant Graves' thyroid tissues. Eur J Endocrinol 168: 137-144.
55. Ito M, Toyoda N, Nomura E, Takamura Y, Amino N, et al. (2011) Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease. Eur J Endocrinol 164: 95-100.
56. Cirello V, Recalcati MP, Muzza M, Rossi S, Perrino M, et al. (2008) Fetal cell microchimerism in papillary thyroid cancer: a possible role in tumor damage and tissue repair. Cancer Res 68: 8482-8488.
57. Matsumoto C, Ito M, Yamada H, Yoshida H, Watanabe M, et al. (2013) Preparation of thyroid follicular cells for mRNA quantification after fluorescence-activated cell sorting. Scand J Clin Lab Invest 73: 245-252.